UMN Pharma Receives Investment From Tokyo Engineering Company
This article was originally published in PharmAsia News
Executive SummaryAkita-based UMN Pharma signed a contract with Tokyo-based IHI Plant Engineering, which will design manufacturing equipment for UMN's new avian flu vaccine production plant in Akita Prefecture in early 2009. The total contract's estimated value is ¥2 billion. To strengthen the cooperation with UMN Pharma, IPEC invested ¥200 million and acquired 2 percent of UMN shares. IPEC also plans to further invest ¥200 million in the bioventure company. (Click here for more - Japanese language
You may also be interested in...
New real-world data, presented at a recent diabetes conference in Madrid, showed that Abbott's FreeStyle Libre system provided several clinical benefits for patients with diabetes.
HBW Executive Decisions: Perrigo Americas, Nutraceutical International Helm Changes, ABC Farnsworth Award, More
Myos Rens hires Eric LeGrand as special advisor for sports nutrition; Perrigo Consumer Americas chief Jeff Needham will be succeeded by Rich Sorota; Nutraceutical International appoints Monty Sharma to replace Chad Clawson at the helm; American Botanical Council’s Farnsworth Award goes to Rachel Mata; and Herbalife’s John Agwunobi will be chairman as well as CEO.
Philips Expert Urges Device Makers: Update Quality Systems To Conform To Revised Risk Standard ISO 14971
It’s time for manufacturers to begin adopting the new 2019 version of ISO 14971, the international standard for risk management widely used by industry. But firms need to do more work than just changing the date on risk-related procedures and documents to “2019,” says Jos Van Vroonhoven, a senior manager at Philips Healthcare who was intimately involved with the standard’s redo. From conducting gap assessments to creating cross-functional teams, both Van Vroonhoven and longtime industry expert Don Powers tell Medtech Insight how firms can keep their quality systems up-to-date to conform to ISO 14971:2019.